Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 12, 2008, Pages 1889-1895

  Sica, Gabriel ^a   Wagner, Patrick L ^a   Altorki, Nassar ^a   Port, Jeffrey ^a   Lee, Paul C ^a   Vazquez, Madeline F ^a   Saqi, Anjali ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CARCINOID; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SMALL CELL CARCINOMA;

AGED; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 57349147752     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Lillington G. A Diagnostic Approach to Chest Diseases. 3rd ed. Baltimore, Md: Williams & Wilkins; 1987.
3. Casali C, Stefani A, Paci M, Morandi U, Lodi R. Surgical management of solitary pulmonary nodules: an unexpected lucky case. J Cardiovasc Surg (Torino). 2001;42:271-273.
4. Darvishian F, Ginsberg MS, Klimstra DS, Brogi E. Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer. Hum Pathol. 2006;37:839-844.
5. Tanaka F, Li M, Hanaoka N, et al. Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg. 2005;79:1711-1714, discussion 1714-1715.
6. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
7. Koscielny S, Le MG, Tubiana M. The natural history of human breast cancer: the relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer. 1989;59:775-782.
8. Kayser K, Biechele U, Kayser G, et al. Pulmonary metastases of breast carcinomas: ligandohistochemical, nuclear, and structural analysis of primary and metastatic tumors with emphasis on period of occurrence of metastases and survival. J Surg Oncol. 1998;69(3):137-146.
9. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403-405, discussion 406.
10. Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001;93:330-336.
11. Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer RM Jr. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg. 1994;108:153-157.
12. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer. 1996;67:357-364.
13. Kaufmann O, Kother S, Dietel M. Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods. Mod Pathol. 1998;11:357-363.
14. Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology. 2002;40:215-222.
15. Saqi A, Oster MW, Vazquez MF. Metastatic mammary carcinomas with endocrine features: potential diagnostic pitfalls. Diagn Cytopathol. 2005;33:49-53.
16. Tse GM, Ma TK, Chu WC, Lam WW, Poon CS, Chan WC. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. Mod Pathol. 2004;17:568-572.
17. Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003;34:1001-1008.
18. Radhi JM. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology. 2000;36(2):156-160.
19. Sternberg DI, Sonett JR. Surgical therapy of lung metastases. Semin Oncol. 2007;34:186-196.
20. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
21. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223.
22. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415-420.
23. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445-452.
24. Mirimanoff RO, Wagenknecht L, Hunziker N. Long-term complete remission of malignant melanoma with tamoxifen. Lancet. 1981;1(8234):1368-1369.
25. Di Leo A, Linsalata M, Cavallini A, Messa C, Russo F. Sex steroid hormone receptors, epidermal growth factor receptor, and polyamines in human colorectal cancer. Dis Colon Rectum. 1992;35:305-309.
26. Singh S, Sheppard MC, Langman MJ. Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut. 1993;34:611-615.
27. Friedman MA, Demanes DJ, Hoffman PG Jr. Hepatomas: hormone receptors and therapy. Am J Med. 1982;73:362-366.
28. Greenway B, Iqbal MJ, Johnson PJ, Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed). 1981;283:751-753.
29. Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors: an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70:2268-2277.
30. Wu CW, Chi CW, Chang TJ, Lui WY, P'Eng FK. Sex hormone receptors in gastric cancer. Cancer. 1990;65:1396-1400.
31. Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. Cancer Res. 1985;45:4206-4214.
32. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res. 1990;50:6632-6635.
33. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med. 1994;118:630-632.
34. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res. 1996;16(6B):3803-3806.
35. Feyrter F, Hartmann G. [On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) mammae.]. Frankf Z Pathol. 1963;73:24-39.
36. Bofin AM, Qvigstad G, Waldum C, Waldum HL. Neuroendocrine differentiation in carcinoma of the breast: tyramide signal amplification discloses chromogranin A-positive tumour cells in more breast tumours than previously realized. APMIS. 2002;110:658-664.
37. Scopsi L, Andreola S, Pilotti S, et al. Mucinous carcinoma of the breast: a clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation. Am J Surg Pathol. 1994;18:702-711.
38. Scopsi L, Andreola S, Pilotti S, et al. Argyrophilia and granin (chromogranin/secretogranin) expression in female breast carcinomas: their relationship to survival and other disease parameters. Am J Surg Pathol. 1992;16:561-576.
39. Maluf HM, Koerner FC. Solid papillary carcinoma of the breast: a form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol. 1995;19:1237-1244.
40. Capella C, Eusebi V, Mann B, Azzopardi JG. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology. 1980;4:613-630.
41. Aihara T, Nakajima T. Sclerosing hemangioma of the lung: pathological study and enzyme immunoassay for estrogen and progesterone receptors. Acta Pathol Jpn. 1993;43:507-515.
42. Mendelson CR, MacDonald PC, Johnston JM. Estrogen binding in human fetal lung tissue cytosol. Endocrinology. 1980;106:368-374.
43. Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: an immunohistochemical study. Am J Respir Crit Care Med. 2000;161(3, pt 1):1002-1009.
44. Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med. 2000;124:1467-1470.
45. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol. 2002;188(1-2):125-140.
46. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer. 2002;37(2):153-159.
47. Devouassoux-Shisheboran M, Hayashi T, Linnoila RI, Koss MN, Travis WD. A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol. 2000;24:906-916.
48. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol. 1991;96:529-535.
49. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 2005;11:5084-5089.
50. Caltagirone S, Ranelletti FO, Rinelli A, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol. 1997;17:51-59.
51. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2002;8(2):69-73.